190 related articles for article (PubMed ID: 37091809)
1. Pan-cancer analysis of super enhancer-induced PRR7-AS1 as a potential prognostic and immunological biomarker.
Wang R; Liu N; Li G; Liu J; Ma X; Liu X; Li J
Front Genet; 2023; 14():1160599. PubMed ID: 37091809
[No Abstract] [Full Text] [Related]
2. PRR7-AS1 Correlates with Immune Cell Infiltration and Is a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma.
Lu Y; Chen S; Wang Q; Zhang J; Pei X
J Oncol; 2022; 2022():1939368. PubMed ID: 36059812
[TBL] [Abstract][Full Text] [Related]
3. A pan-cancer analysis indicates long noncoding RNA HAND2-AS1 as a potential prognostic, immunomodulatory and therapeutic biomarker in various cancers including colorectal adenocarcinoma.
Samadi P; Shahnazari M; Shekari A; Maghool F; Jalali A
Cancer Cell Int; 2023 Dec; 23(1):307. PubMed ID: 38042769
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA PRR7-AS1 promotes osteosarcoma progression via binding RNF2 to transcriptionally suppress MTUS1.
Chen-Xi G; Jin-Fu X; An-Quan H; Xiao Y; Ying-Hui W; Suo-Yuan L; Cong S; Tian-Ming Z; Jun S
Front Oncol; 2023; 13():1227789. PubMed ID: 38033505
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of ZFPM2-AS1 prognostic value, immune microenvironment, drug sensitivity, and co-expression network: from gastric adenocarcinoma to pan-cancers.
Chen D; Wang M; Jiang X; Xiong Z
Discov Oncol; 2022 Apr; 13(1):24. PubMed ID: 35416526
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of the Roles and Driving Forces of RAB42.
Zheng M; Wang W; Bu Y; Liu J; Ma J; Wang R; Ren X; Lu Z; Li J; Cai J
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671428
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma.
Liu J; Yin J; Wang Y; Cai L; Geng R; Du M; Zhong Z; Ni S; Huang X; Yu H; Bai J
Biol Proced Online; 2022 Jul; 24(1):9. PubMed ID: 35836132
[TBL] [Abstract][Full Text] [Related]
8. Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer.
Yang S; Zou X; Yang H; Li J; Zhang A; Zhang L; Li C; Zhu L; Ma Z
Front Genet; 2022; 13():854211. PubMed ID: 35571043
[No Abstract] [Full Text] [Related]
9. MXD3 as an onco-immunological biomarker encompassing the tumor microenvironment, disease staging, prognoses, and therapeutic responses in multiple cancer types.
Wu SY; Lin KC; Lawal B; Wu ATH; Wu CZ
Comput Struct Biotechnol J; 2021; 19():4970-4983. PubMed ID: 34584637
[TBL] [Abstract][Full Text] [Related]
10. Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis.
Wu L; Liao W; Wang X; Zhao Y; Pang J; Chen Y; Yang H; He Y
Bioengineered; 2021 Dec; 12(2):10302-10318. PubMed ID: 34709970
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker.
Yang Y; Liu Q; Guo X; Yuan Q; Nian S; Kang P; Xu Z; Li L; Ye Y
J Oncol; 2022; 2022():8115474. PubMed ID: 36090896
[TBL] [Abstract][Full Text] [Related]
14.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
15. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
[TBL] [Abstract][Full Text] [Related]
16. Gender specific eRNA TBX5-AS1 as the immunological biomarker for male patients with lung squamous cell carcinoma in pan-cancer screening.
Yan T; Wang K; Zhao Q; Zhuang J; Shen H; Ma G; Cong L; Du J
PeerJ; 2021; 9():e12536. PubMed ID: 34900441
[TBL] [Abstract][Full Text] [Related]
17. The value of
Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
[TBL] [Abstract][Full Text] [Related]
18. Novel LncRNA ZFHX4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer.
Wang X; Wang Y; Sun F; Xu Y; Zhang Z; Yang C; Zhang L; Lou G
Front Oncol; 2022; 12():945518. PubMed ID: 35903691
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analyses identify MIR210HG overexpression, epigenetic regulation and oncogenic role in human tumors and its interaction with the tumor microenvironment.
Yadav G; Kulshreshtha R
Life Sci; 2024 Feb; 339():122438. PubMed ID: 38242493
[TBL] [Abstract][Full Text] [Related]
20. Integrated Clinical and Prognostic Analysis of the m
Cao L; Zeng B; Wang Y; Wang X; Qin Y; Zhang C; Wu M; Wang J; Zhang X; Ma L
J Cancer; 2022; 13(15):3623-3639. PubMed ID: 36606187
[No Abstract] [Full Text] [Related]
[Next] [New Search]
